Mendus AB (CHIX:IMMUS) OCF Margin %: 0.00% (As of Mar. 2026)


CHIX:IMMUS Mendus AB CHIX:IMMUS
27 GF Score
Price kr32.70
! 2 Warning Signs
View Full Analysis

What is Mendus AB OCF Margin %?

Mendus AB CHIX:IMMUS 27 OCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates CHIX:IMMUS with a GF Score™ of 27/100. The stock has 2 warning signs investors should review. Among 949 Biotechnology companies, Mendus AB ranks worse than 105373.97% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Mendus AB's Cash Flow from Operations for the three months ended in Mar. 2026 was kr-20.80 Mil. Mendus AB's Revenue for the three months ended in Mar. 2026 was kr0.00 Mil. Therefore, Mendus AB's OCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, Mendus AB's current OCF Yield % is -23.26%.

The historical rank and industry rank for Mendus AB's OCF Margin % or its related term are showing as below:


CHIX:IMMUs's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -64.23
* Ranked among companies with meaningful OCF Margin % only.

Mendus AB OCF Margin % Related Terms

Mendus AB OCF Margin % Historical Data

* Premium members only.

The historical data trend for Mendus AB's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mendus AB OCF Margin % Chart

Mendus AB Annual Data
Trend Jun16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Mendus AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
CHIX:IMMUS
27GF Score
Mendus AB CHIX:IMMUS
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mendus AB OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Mendus AB's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-81.532/0
= %

Mendus AB's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin=Cash Flow from Operations (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-20.798/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
Mendus AB (CHIX:IMMUS) has a OCF Margin % of 0.00% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Mendus AB and its competitors. According to the industry distribution chart, Mendus AB ranks #999999 out of 949 companies in the Biotechnology industry.
Is Mendus AB's OCF Margin % too high?
Mendus AB's current OCF Margin % is 0.00%. Based on the distribution chart, Mendus AB ranks #999999 out of 949 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Mendus AB has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Mendus AB's OCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Mendus AB ranks #999999 out of 949 companies for OCF Margin %. This places Mendus AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Mendus AB and its competitors. Mendus AB's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mendus AB stock overvalued right now?
Mendus AB (CHIX:IMMUS) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. Mendus AB's overall GF Score™ is 27/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Mendus AB (CHIX:IMMUS), the current OCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Mendus AB Business Description

Other Exchanges IMMU:Sweden1YG0:Germany
Address Vastra Tradgardsgatan 15, Stockholm, SWE, 11153
Mendus AB is a clinical-level biopharmaceutical company based on the company's allogeneic dendritic cell biology focused on the development of immunotherapies that address tumor recurrence and hard-to-treat established tumors. Its operations consist of research and development for pharmaceuticals. The company's Pipeline includes: Vididencel, and Ilixadencel.
27GF Score

Get the complete analysis for CHIX:IMMUS

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr32.70
Price